SAN JOSE, Calif., Nov. 5, 2012 /PRNewswire/ -- Ariosa Diagnostics today announced that it will present data from two recent studies on non-invasive prenatal testing (NIPT) at the American Society of Human Genetics (ASHG) Annual Meeting at The Moscone Center in San Francisco, Calif. from Nov. 6 - 11, 2012. The studies highlight a directed cell-free (cfDNA) analysis method of NIPT.

(Logo: http://photos.prnewswire.com/prnh/20121105/NE05794LOGO)

A poster titled "Non-invasive Chromosomal Evaluation (NICE) Study: Results of a Multicenter, Prospective, Cohort Study for Detection of Fetal Trisomy 21 and Trisomy 18," examines the performance of Ariosa's Harmony Prenatal Test, a directed cfDNA analysis method of detecting fetal trisomies. The NICE study represents the largest cohort study in NIPT. Pregnant women at gestational age 10 weeks or later were enrolled from 50 clinical sites in the U.S. and Europe. The poster will be presented on Thursday, Nov. 8, from 3:15 - 4:15 p.m. PST in The Moscone Center Exhibit Hall, Lower Level South.

A second poster titled "The Fetal Fraction of cell-free DNA in Maternal Plasma is Not Affected by a priori Risk of Fetal Trisomy," examines possible clinical factors that might influence the fetal fraction of cfDNA in maternal plasma. The amount of fetal cfDNA in maternal plasma is a major determinant of the ability to detect trisomy. A comparative analysis shows no difference in fetal cfDNA levels between high- and low-risk pregnant women providing support that NIPT performance will be just as robust in a general pregnancy population. This poster will be presented on Thursday, Nov. 8, from 3:15 - 4:15 p.m. PST in The Moscone Center Exhibit Hall, Lower Level South.

For more information about Ariosa and the company's directed cfDNA analysis method of NIPT, please visit us at Booth #1609.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.

SOURCE Ariosa Diagnostics